Nov 18, 2026: a secondary priced 18% below the close
Ardent Health closed Tuesday, Nov 17, at $17.75. After the close the selling holders launched the offering, and extended trading fell to $14.86, 16.3% below the close. The deal was priced overnight at $14.50. Premarket trading on Wednesday started at $15.00 and slid to $13.76 by 8:25am.
The stock opened at $13.75 and touched $13.46 in the first minutes, 24.2% below the close and 7.2% below the offering price. Buyers then stepped in: it reached $14.53 at 9:55am and traded at $14.39 at 10:11am on 2.5 million shares, already about three times its 20-day average volume for a full day.
What pushed it down:
- The discount. At $14.50 the sellers took 18.3% less than the Nov 17 close and 19.9% less than the $18.10 close on Nov 16, the price shown in the preliminary prospectus.
- The size. The 8 million shares, plus up to 1.2 million more if the underwriters use their option, are about 5.7% to 6.5% of the 140.9 million shares outstanding on Nov 2. At 10:11am Ardent's daily volume of 2.5 million shares compares with about 0.8 million on a normal day.
- The run before it. The stock rose from $11.71 on Nov 3 to $18.10 on Nov 16, 55%, after third-quarter results on Nov 4 and the Boone Health deal on Nov 12. Holders who sell after a run like that set the price of the next trade.
The other hospital stocks barely moved. At 10:10am HCA was down 2.1%, Tenet 1.1%, Universal Health 0.6% and Community Health flat, while the health care fund XLV was down 0.9%. Our explainer on secondary offerings covers why a holder's sale weighs on price even when no new shares are created, and more of the session's movers are in today's biggest stock moves.
After the drop, RSI(14) stood at 48, the shares sat 14% above their 50-day average and 36% above their 200-day average, and they were 23% below the 52-week high of $18.57.
The numbers
| Measure | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Total revenue | $1,625M | $1,577M | +3.1% |
| Net income attributable to Ardent | $45M | ($23M) | |
| Diluted EPS | $0.31 | ($0.17) | |
| Adjusted EBITDA | $138M | $45M | +204% |
| Adjusted EBITDA margin | 8.5% | 2.9% | |
| Adjusted admissions | 91,933 | 89,328 | +2.9% |
| Emergency room visits | 163,909 | 161,198 | +1.7% |
At Sept. 30 Ardent had $766 million of cash, $1.1 billion of debt, $1 billion of available liquidity and lease-adjusted net leverage of 2.5 times. It bought back 1.0 million shares for $11 million in the third quarter, and the board added $25 million to the program, leaving about $48 million at Sept. 30 before today's 1.5 million share purchase. Our explainer on when buybacks matter as catalysts covers why a company buying inside a holder's sale can steady a stock, and our piece on EV to EBITDA covers the multiple hospital stocks are usually compared on.
The bull case
Ardent's volumes are improving: adjusted admissions grew 2.9% in the third quarter after 2.5% in the second, and emergency room visits rose 1.7% after 0.2%. Chief executive Dave Caspers said the company enters the fourth quarter "with confidence in the trajectory of our business," and its cost program remains on track for at least $70 million of savings this year. The Boone Health deal adds a system with about $480 million of revenue for $47 million in cash and is expected to add 6% to 8% to adjusted EBITDA in its third year. At 0.31 times sales the stock is priced like a company whose margins are not improving, while guidance says they are. The concurrent buyback means part of today's supply goes straight back to the company.
The risks
- A controlling holder. Equity Group Investments' affiliate will still own 70.1 million shares, about 50.3% of the vote, and has registration rights. Our explainer on lock-up expirations covers what tends to happen when a lock-up ends.
- Surgeries. Inpatient surgeries fell 5.0% and total surgeries 1.9% in the third quarter, and surgeries carry higher revenue per case.
- Deal spending. Boone Health comes with a $200 million capital commitment over 10 years, on top of Ardent's own spending plans.
- Short interest. About 15.7% of the float is sold short, which can amplify moves either way.
What comes next
- The offering closes Nov 19, 2026. Whether the underwriters buy the extra 1.2 million shares in the next 30 days.
- Boone Health. Regulatory steps toward a first-quarter 2027 close.
- The lock-up ends Feb 15, 2027. Any further sale by Equity Group Investments or Ventas after that date, and fourth-quarter results with 2027 guidance, expected around the same time.

